250 related articles for article (PubMed ID: 15933751)
1. The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients.
Day DG; Sharpe ED; Atkinson MJ; Stewart JA; Stewart WC
Eye (Lond); 2006 May; 20(5):583-90. PubMed ID: 15933751
[TBL] [Abstract][Full Text] [Related]
2. A new measure of patient satisfaction with ocular hypotensive medications: the Treatment Satisfaction Survey for Intraocular Pressure (TSS-IOP).
Atkinson MJ; Stewart WC; Fain JM; Stewart JA; Dhawan R; Mozaffari E; Lohs J
Health Qual Life Outcomes; 2003 Nov; 1():67. PubMed ID: 14617372
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
4. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.
Lesk MR; Koulis T; Sampalis F; Sampalis JS; Bastien NR
Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Bottoli A; Fogagnolo P
Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of bimatoprost for the treatment of open-angle glaucoma and ocular hypertension: a three-month, open-label study in community-based practices in Thailand.
Wanichwecha-Rungruang B; Iemsomboon W
J Med Assoc Thai; 2005 Sep; 88(9):1228-35. PubMed ID: 16536109
[TBL] [Abstract][Full Text] [Related]
8. Success rates for switching to dorzolamide/timolol fixed combination in timolol responders who are insufficiently controlled by latanoprost monotherapy.
Sonty S; Henry JC; Sharpe ED; Weiss MJ; Stewart JA; Nelson LA; Stewart WC
Acta Ophthalmol; 2008 Jun; 86(4):419-23. PubMed ID: 18039347
[TBL] [Abstract][Full Text] [Related]
9. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
[TBL] [Abstract][Full Text] [Related]
10. A multicentre evaluation of the effect of patient education on acceptance of hyperaemia associated with bimatoprost therapy for glaucoma or ocular hypertension.
Trattler W; Noecker RJ; Earl ML
Adv Ther; 2008 Mar; 25(3):179-89. PubMed ID: 18351298
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
Noecker RJ; Walt JG
Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S15-21. PubMed ID: 16389056
[TBL] [Abstract][Full Text] [Related]
12. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.
Denis P; Lafuma A; Khoshnood B; Mimaud V; Berdeaux G
Curr Med Res Opin; 2007 Mar; 23(3):601-8. PubMed ID: 17355741
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials.
Aptel F; Cucherat M; Denis P
J Glaucoma; 2008 Dec; 17(8):667-73. PubMed ID: 19092464
[TBL] [Abstract][Full Text] [Related]
15. Inter-visit intraocular pressure range: an alternative parameter for assessing intraocular pressure control in clinical trials.
Varma R; Hwang LJ; Grunden JW; Bean GW
Am J Ophthalmol; 2008 Feb; 145(2):336-42. PubMed ID: 18222194
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension.
Kałuzny J; Sobecki R; Czechowicz-Janicka K; Kecik D; Kałuzny BJ; Stewart JA; Stewart WC
Acta Ophthalmol; 2008 Dec; 86(8):860-5. PubMed ID: 18721251
[TBL] [Abstract][Full Text] [Related]
17. Midterm response with latanoprost therapy in german ocular hypertension patients.
Thelen U; Christ T; Schnober D; Hofstetter HJ; Stewart WC
Curr Eye Res; 2007 Jan; 32(1):51-6. PubMed ID: 17364735
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study.
Casson RJ; Liu L; Graham SL; Morgan WH; Grigg JR; Galanopoulos A; Crawford A; House PH
J Glaucoma; 2009; 18(8):582-8. PubMed ID: 19826386
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the role of travoprost 0.004% ophthalmic solution in the management of open angle glaucoma and ocular hypertensive patients.
Chiselită D;
Oftalmologia; 2007; 51(2):81-6. PubMed ID: 17937041
[TBL] [Abstract][Full Text] [Related]
20. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%.
García-Feijoo J; Martínez-de-la-Casa JM; Castillo A; Méndez C; Fernández-Vidal A; García-Sánchez J
Curr Med Res Opin; 2006 Sep; 22(9):1689-97. PubMed ID: 16968572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
